Unicycive Therapeutics Dividend

Dividend criteria checks 0/6

Unicycive Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	2.9%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	-US$0.84
Dividend yield forecast in 3Y	31.4%

Recent dividend updates

No updates

Recent updates

Unicycive stock soars 25% as kidney drug UNI-494 shows promise in preclinical study in rats

Sep 07

Unicycive Therapeutics GAAP EPS of -$0.24

Aug 16

Unicycive inks licensing deal for kidney disease drug Renazorb in Asia

Jul 18

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if UNCY's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if UNCY's dividend payments have been increasing.

Dividend Yield vs Market

Unicycive Therapeutics Dividend Yield vs Market

How does UNCY dividend yield compare to the market?
Segment	Dividend Yield
Company (UNCY)	n/a
Market Bottom 25% (US)	1.5%
Market Top 25% (US)	4.7%
Industry Average (Biotechs)	2.9%
Analyst forecast in 3 Years (UNCY)	31.4%

Notable Dividend: Unable to evaluate UNCY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate UNCY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate UNCY's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as UNCY has not reported any payouts.

Unicycive Therapeutics Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

Unicycive Therapeutics, Inc., Annual General Meeting, Jun 20, 2024

Price target increased by 15% to US$5.30

Forecast to breakeven in 2026

Consensus EPS estimates fall by 71%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Unicycive Therapeutics, Inc. announced that it has received $50 million in funding

Unicycive Therapeutics, Inc. announced that it expects to receive $50 million in funding

Consensus revenue estimates decrease by 11%

New minor risk - Profitability

Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate

Will Unicycive Therapeutics (NASDAQ:UNCY) Spend Its Cash Wisely?

Forecast to breakeven in 2025

Unicycive Therapeutics Reaches Alignment with the Fda on Path to File New Drug Application for Oxylanthanum Carbonate

Unicycive Therapeutics Receives Non-Compliance Notices from Nasdaq

Unicycive Therapeutics, Inc. Announces Appointment of Sara Kenkare-Mitra to Board of Directors

New minor risk - Profitability

Consensus EPS estimates upgraded to US$1.17 loss

We're Keeping An Eye On Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn Rate

New major risk - Shareholder dilution

No longer forecast to breakeven

Unicycive Therapeutics, Inc. Provides Regulatory Update on Lanthanum Dioxycarbonate Program

Unicycive Therapeutics Receives Written Notification from Nasdaq Regarding Minimum Market Value Requirement Under Nasdaq Listing Rule 5550(b)(2)

Unicycive Therapeutics, Inc. announced delayed 10-Q filing

Price target decreased by 21% to US$7.40

Consensus revenue estimates increase by 33%

Forecast to breakeven in 2025

Unicycive Therapeutics (NASDAQ:UNCY) Will Have To Spend Its Cash Wisely

Unicycive Therapeutics Receives Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

Unicycive Therapeutics, Inc. Announces Medicines and Healthcare Products Regulatory Agency in the United Kingdom Complete Review of the Clinical Trial Application and Issue A Notice of Acceptance for UNI-494 First-In-Human Phase 1

Unicycive Therapeutics, Inc. Reports Key Findings of Uni-494 Efficacy in Preclinical Animal Model of Geographic Atrophy

Unicycive Completes Enrollment of Pivotal Bioequivalence Study for Renazorb™ (Lanthanum Dioxycarbonate), an Investigational Treatment for Hyperphosphatemia in Chronic Kidney Disease (Ckd) Patients on Dialysis

Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Acute Kidney Injury (AKI)

Unicycive stock soars 25% as kidney drug UNI-494 shows promise in preclinical study in rats

Unicycive Therapeutics GAAP EPS of -$0.24

Unicycive Therapeutics, Inc. Receives Written Notice from the Nasdaq Stock Market, LLC

Unicycive inks licensing deal for kidney disease drug Renazorb in Asia

Unicycive Therapeutics, Inc. Initiates Pivotal Clinical Bioequivalence Study of Renazorb to Treat Hyperphosphatemia

Unicycive Therapeutics, Inc., Annual General Meeting, Jun 15, 2022

Unicycive Therapeutics, Inc. Receives Confirmatory Guidance on Renazorb Regulatory Pathway

Unicycive Therapeutics, Inc. has completed an IPO in the amount of $25 million.

Stability and Growth of Payments

Dividend Yield vs Market

Earnings Payout to Shareholders

Cash Payout to Shareholders

Discover strong dividend paying companies